Dividends & Income
To screen ETFs by asset class, performance, yield and more, check out the
Author Following Options:
Follow this author
See their articles on your Seeking Alpha homepage and in your feed.
Real-time alerts on this author
Get their new articles emailed to you as they are published.
Daily digest on all my authors
Get all your favorite authors’ new articles emailed to you in one daily digest.
View BinaryLeverage's Comments
Alexza's Adasuve May Not Be Ready For FDA Approval
Something I wonder about is how many of the acutely agitated patients will actually be suitable candidates for this drug. As I understand it, the pivotal studies required patient consent and therefore selected for individuals who could be instructed in how to use the inhaler and who were motivated to comply.
Many of the patients I have seen with acute agitation presented in the ER in a paranoid, aggressive state or created chaos in hospital wards in the middle of the night throwing furniture through windows. There is just no way that Adasuve would be an option for patients like this.
The overall market also seems potentially very small. I read a study (admittedly it was a few years old) that claimed there were ~1M ER admissions for psychotic episodes per year in the US. Additional episodes may occur in different settings but the numbers are hardly overwhelming.
Dec 11, 2012. 05:38 PM
Link to Comment
More on ALXA by BinaryLeverage
Xignite quote data
© 2015 Seeking Alpha